Imiquimod (R 837) | TLR7 Agonist

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	US Stock	Global Stock
1g	łÇò¶ÊÊ	Inquiry	Inquiry
5g	łÿÿ¶ÊÊ	Inquiry	Inquiry
10g	łÇÊÿ¶ÊÊ	Inquiry	Inquiry
25g	łËÿÿ¶ÊÊ	Inquiry	Inquiry
100g	łóÍÊ¶ÊÊ	Inquiry	Inquiry

NCT00147771	Scleroderma, Localized	Phase 3	Completed	-	Canada, Ontario ... More >> The Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Less <<
NCT01795313	Ependymoma	Not Applicable	Recruiting	January 2020	United States, Pennsylvania ... More >> Children's Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Mary Petrany, RN 412-692-8047 petranym@upmc.edu Less <<
NCT00581425	Basal Cell Carcinoma	Phase 4	Completed	-	United States, Texas ... More >> University of Texas Health Science Center of Houston Dermatology Clinic Houston, Texas, United States, 77030 Less <<
NCT00079300	Non-melanomatous Skin Cancer	Phase 1	Completed	-	United States, Maryland ... More >> NIH - Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892-1182 Less <<
NCT00066872	Non-melanomatous Skin Cancer	Phase 3	Completed	-	United Kingdom ... More >> Chesterfield Royal Hospital Chesterfield, England, United Kingdom, S44 5BL Queen's Medical Centre Nottingham, England, United Kingdom, NG7 2UH Solihull Hospital Solihull, England, United Kingdom, B91 2JL Less <<
NCT00788164	Cervical Cancer ... More >> Precancerous Condition HPV Disease Human Papilomavirus Less <<	Phase 1	Recruiting	June 2020	United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231-2410 Contact: Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce 410-955-8804 jhcccro@jhmi.edu Less <<
NCT00463359	Basal Cell Carcinoma	Not Applicable	Unknown	-	United Kingdom ... More >> Dermatology Department, Western Infirmary Not yet recruiting Glasgow, Lanarkshire, United Kingdom, G11 6NT Contact: Robert Herd, Consultant Dermatologist +441412111000 ext 6259 robert.herd@northglasgow.scot.nhs.uk Contact: Areti Makrygeorgou, Staff Grade Dr +441412111000 ext 2903 amakrygeorgou@hotmail.com Sub-Investigator: Areti Makrygeorgou, Staff Grade Dr Sub-Investigator: Robert Herd, Consultant Dermatologist Principal Investigator: Lorna MacKintosh, Specialist Registrar Less <<
NCT00894647	Actinic Keratosis	Phase 3	Completed	-	United States, California ... More >> Dermatology Research Associates Los Angeles, California, United States, 90045 Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Florida Spencer Dermatology & Skin Surgery Center St. Petersberg, Florida, United States, 33705 Palm Beach Dermatology West Palm Beach, Florida, United States, 33401 United States, Georgia MedaPhase, Inc. Newman, Georgia, United States, 30263 United States, Illinois Evanston Northwestern Healthcare Skokie, Illinois, United States, 60077 United States, Nebraska Skin Specialists PC Omaha, Nebraska, United States, 68144 United States, New Mexico Academic Dermatology Association Albuquerque, New Mexico, United States, 87106 United States, New York DermResearchCenter of New York Stony Brook, New York, United States, 11790 United States, North Carolina Wake Forest Univ School of Medicine Winston-Salem, North Carolina, United States, 27157 United States, Oregon Oregon Medical Research Center Portland, Oregon, United States, 97223 United States, Texas DermResearch Inc. Austin, Texas, United States, 78759 Dermatology Treatment and Research Center Dallas, Texas, United States, 75230 Progressive Clinical Research San Antonio, Texas, United States, 78229 Canada, British Columbia Guildford Dermatology Specialists Surrey, British Columbia, Canada, V3R6A7 Canada, New Brunswick Clinique de Dermatologie Moncton, New Brunswick, Canada, E1C 8X3 Canada, Ontario Ultranova Skincare Barrie, Ontario, Canada, L4M 6L2 Probity Medical Research Waterloo, Ontario, Canada, N2J 1C4 Less <<
NCT00294320	Actinic Keratosis	Phase 3	Completed	-	France ... More >> Hopital L'Archet 2 Nice, Cedex 3, France Less <<
NCT00894647	-		Completed	-	-
NCT00603798	Actinic Keratosis	Phase 3	Completed	-	-
NCT00177021	Alopecia Areata	Phase 4	Completed	-	United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT00603798	-		Completed	-	-
NCT00142454	Malignant Melanoma	Phase 1	Completed	-	United States, New York ... More >> NYU Cancer Institute New York City, New York, United States, 10016 Less <<
NCT00605176	Actinic Keratoses	Phase 3	Completed	-	-
NCT00257530	Cutaneous Leishmaniasis	PHASE3	COMPLETED	2025-06-06	UPCH, Cusco, Peru\|IMT Alexande... More >>r Von Humboldt, Lima, Peru Less <<
NCT00605176	-		Completed	-	-
NCT00204555	Carcinoma, Basal Cell	PHASE4	COMPLETED	2025-09-05	Skin Cancer Program, Departmen... More >>t of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, 72076, Germany Less <<
NCT00110682	Keratosis Act... More >>inic Keratosis Less <<	Phase 4	Completed	-	Canada, British Columbia ... More >> DermResearch @ 888 Inc Vancouver, British Columbia, Canada, V4C 6X4 Canada, Ontario Windsor Clinical Research Windsor, Ontario, Canada Canada, Quebec Centre de Recherche Dermatologique, CRDQ Sainte-Foy, Quebec, Canada, G1V 4X7 Less <<
NCT00189280	Carcinoma, Basal Cell	PHASE3	COMPLETED	2025-10-07	Service de DermatologieH?pital... More >> Dupuytren, Limoges, 87042, France Less <<
NCT03180684	Vulvar High Grade Squamous Int... More >>raepithelial Lesion (HSIL) Vulvar Dysplasia Vulvar Intraepithelial Neoplasia (VIN) VIN2 VIN3 Pre-cancerous Lesions of the Vulva Human Papillomavirus (HPV) Less <<	Phase 2	Recruiting	September 2021	-
NCT03071679	Healthy	Phase 1	Completed	-	Netherlands ... More >> LUMC/Centre for Human Drug Research Leiden, Netherlands Less <<
NCT01212549	Basal Cell Carcinoma	Phase 3	Completed	-	Greece ... More >> Department for Skin and Venereal Diseases, University Hospital Ioannina, Greece, 45110 Less <<
NCT00031759	Cervical Cancer ... More >> Precancerous Condition Less <<	Phase 2	Completed	-	United States, Arizona ... More >> CCOP - Mayo Clinic Scottsdale Oncology Program Scottsdale, Arizona, United States, 85259-5404 United States, Florida Mayo Clinic Jacksonville, Florida, United States, 32224 United States, Hawaii MBCCOP - Hawaii Honolulu, Hawaii, United States, 96813 United States, Illinois CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Kansas CCOP - Wichita Wichita, Kansas, United States, 67214-3882 United States, Michigan CCOP - Michigan Cancer Research Consortium Ann Arbor, Michigan, United States, 48106 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, South Dakota CCOP - Sioux Community Cancer Consortium Sioux Falls, South Dakota, United States, 57104 Less <<
NCT01413763	Actinic Keratosis	Phase 4	Unknown	April 2013	United States, Florida ... More >> Comprehensive Phase One Fort Meyers, Florida, United States, 33901 Less <<
NCT00821964	Male Breast Cancer ... More >> Recurrent Breast Cancer Skin Metastases Stage IV Breast Cancer Less <<	Phase 2	Completed	-	United States, Washington ... More >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT01453179	Actinic Keratosis	Phase 4	Completed	-	Austria ... More >> Medical University Graz, University Clinic for Dermatology and Venerology Graz Graz, Austria, A-8036 Medical Practice Maria Enzersdorf, Austria, A-2344 Medical University Vienna, Department for General Dermatology Vienna, Austria, A-1090 Germany Medical Supply Center Augsburg, Germany, D-86163 Licca Clinical Research Institute, Clinic for Dermatolgy and Surgery Augsburg, Germany, D-86179 Medical Practice Berlin, Germany, D-10437 Medical Practice Duelmen, Germany, D-48249 Medical Practice Germering, Germany, D-82110 Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venerology Magdeburg, Germany, D-39120 Medical Practice Mahlow, Germany, D-15831 Department of Dermatology Johannes Gutenberg-University Mainz, Clinical Research Center Mainz, Germany, D-55131 Medical Practice Markkleeberg, Germany, D-04416 Medical Practice for Dermatology and Medical Cosmetics Mönchengladbach, Germany, D-41061 Medical Practice Münster, Germany, D-48143 Derma Center Vechta, Clinic for Dermatology Vechta, Germany, D-49377 Centrovital, Medical Practice for Dermatology Witten, Germany, D-58453 Medical Practice for Dermatology and Venerology Wuppertal, Germany, D-42275 Less <<
NCT00821964	-		Completed	-	-
NCT00470392	Psoriasis	Not Applicable	Terminated(Recruiting complete... More >> and administrative termination) Less <<	-	United States, Ohio ... More >> University Hospital Case Medical Center Cleveland, Ohio, United States, 44106 VA Medical Center, Cleveland Cleveland, Ohio, United States, 44106 Less <<
NCT00470392	-		Terminated(Recruiting complete... More >> and administrative termination) Less <<	-	-
NCT00230373	Morphea	Phase 3	Withdrawn(Study never started.... More >>) Less <<	June 2007	Canada, Alberta ... More >> Dr. Marlene Dytoc's clinic Edmonton, Alberta, Canada, T6G 2C8 University of Alberta Edmonton, Alberta, Canada, T6G 2G3 Dr. Loretta Fiorillo's clinic Red Deer, Alberta, Canada, T4N 6R2 Less <<
NCT01502020	Actinic Keratoses	Not Applicable	Completed	-	-
NCT01508884	Chronic Illness	Not Applicable	Completed	-	Hong Kong ... More >> The University of Hong Kong, Queen Mary Hospital Hong Kong, Hong Kong Less <<
NCT01380314	Cutaneous Leishmaniasis	Phase 2	Completed	-	Bolivia ... More >> Cenetrop Santa Cruz, SC, Bolivia, 0000 Less <<
NCT00596336	Chronic Lymphocytic Leukemia	Phase 2	Terminated(Recruitment issues)	-	United Kingdom ... More >> Royal Bournemouth hospital Bournemouth, Dorset, United Kingdom, BH7 7DW Less <<
NCT01400672	Diffuse Intrinsic Pontine Glio... More >>ma Less <<	Phase 1	Completed	-	United States, Minnesota ... More >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT03534947	Basal Cell Carcinoma ... More >> Basal Cell Carcinoma of Skin, Site Unspecified Skin Cancer Invasive Carcinoma Less <<	Phase 2	Not yet recruiting	April 2020	Australia, New South Wales ... More >> Melanoma Institute Australia Not yet recruiting North Sydney, New South Wales, Australia, 2060 Contact: Pascal Guitera, MD PhD +61299117296 pascale.guitera@melanoma.org.au Principal Investigator: Pascale Guitera Less <<
NCT00189241	Basal Cell Carcinoma	Phase 3	Completed	-	Germany ... More >> Univertätsklinik für Dermatologie und Venerologie Magedeburg, Germany Less <<
NCT00314756	Basal Cell Carcinoma	Phase 4	Completed	-	United States, North Carolina ... More >> Wake Forest University Medical Center Winston-Salem, North Carolina, United States, 27157 Less <<
NCT00175643	Actinic Keratoses	Phase 3	Completed	-	Canada, British Columbia ... More >> Clinical Trials Unit, Skin Care Centre, UBC Dermatology Vancouver, British Columbia, Canada, V5Z 4E8 Less <<
NCT01678352	High Risk WHO Grade II Glioma ... More >> Recurrent/Post-Chemotherapy WHO Grade II Glioma Less <<	Early Phase 1	Active, not recruiting	December 2019	United States, Pennsylvania ... More >> University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00115154	Keratosis	Phase 4	Completed	-	United States, Arizona ... More >> Tucson, Arizona, United States, 85710 United States, California Vista, California, United States, 92083 United States, Georgia Atlanta, Georgia, United States, 30263 Newnan, Georgia, United States, 30263 United States, Illinois Buffalo Grove, Illinois, United States, 60089 United States, Indiana Evansville, Indiana, United States, 47713 United States, New Jersey Delran, New Jersey, United States, 08075 United States, New York New York, New York, United States, 10025 Rochester, New York, United States, 14623 United States, North Carolina Greenville, North Carolina, United States, 27834 United States, Oregon Portland, Oregon, United States, 97223 United States, Rhode Island Providence, Rhode Island, United States, 02903 United States, Tennessee Knoxville, Tennessee, United States, 37922 United States, Texas Dallas, Texas, United States, 75246 Houston, Texas, United States, 77030 United States, Virginia Virginia Beach, Virginia, United States, 23454 United States, Washington Wenatchee, Washington, United States, 98801 United States, Wisconsin Milwaukee, Wisconsin, United States, 53209 Less <<
NCT02224599	Progressive Solid Malignancies... More >> Refractory Solid Malignancies Cancer Less <<	Phase 1 Phase 2	Active, not recruiting	March 31, 2019	United States, Texas ... More >> San Antonio, Texas, United States, 78240 Less <<
NCT02960815	Influenza Vaccine	Phase 2	Completed	-	Switzerland ... More >> CHUV Lausanne, Switzerland, 1011 Less <<
NCT00189293	Genital Warts	Phase 4	Completed	-	Italy ... More >> Clinica Ostetrica e Ginecologica Università Politecnica delle Marche Ancona, Italy, 60123 Struttura Complessa di Ostetricia e Ginecologia Ospedale Cardinal Massaia Asti, Italy, 14100 Unità Operativa di Ginecologia Oncologica, RCCS Ospedale Oncologico Bari, Italy, 70100 Servizio Autonomo di Diagnosi Precoce dei Tumori Ginecologici Ospedale Vittorio Emanuele Catania, Italy, 95124 Clinica Ostetrica Ginecologica, Ospedale Careggi Firenze, Italy, 50134 Struttura Complessa Oncologia Chirurgica C Istituto Scientifico dei Tumori IST Genova, Italy, 16132 Servizio di Ginecologia Preventiva, Istituti Clinici di Perfezionamento Milano, Italy, 20122 Clinica Ostetrica Ginecologica Azienda Ospedaliera L. Sacco Milano, Italy Unità di Ginecologia Preventiva e Oncologica Università di Modena e Reggio Emilia Modena, Italy, 41100 Unità Operativa di Ginecologia Oncologica, Ospedale Oncologico M. Ascoli Palermo, Italy, 90127 Ostetricia e Ginecologia, Ospedale S. Maria delle Grazie Pozzuoli, Italy, 80078 Ambulatorio di Colposcopia e Patologia Cervico-Vaginale, Università Cattolica del Sacro Cuore Roma, Italy, 00168 Less <<
NCT00979550	-		Terminated(Failure to enroll e... More >>nough participants) Less <<	-	-
NCT00504023	-		Completed	-	-
NCT00504023	Vulvar Cancer	Not Applicable	Completed	-	United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Ohio Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210-1240 Less <<
NCT00979550	Port Wine Stains	Phase 2	Terminated(Failure to enroll e... More >>nough participants) Less <<	-	United States, Kentucky ... More >> University of Kentucky Division of Plastic Surgery Lexington, Kentucky, United States, 40536-0284 Less <<
NCT00707174	-		Completed	-	-
NCT03196180	High Grade Cervical Intraepith... More >>elial Neoplasia p16 Positive Neoplastic Cells Present Less <<	Phase 1	Not yet recruiting	June 30, 2021	United States, North Carolina ... More >> UNC Lineberger Comprehensive Cancer Center Not yet recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Lisa Rahangdale 919-843-7851 lisa_rahangdale@med.unc.edu Principal Investigator: Lisa Rahangdale Less <<
NCT00799110	Ovarian Cancer ... More >> Primary Peritoneal Cancer Fallopian Tube Cancer Less <<	Phase 2	Active, not recruiting	January 2020	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham & Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Less <<
NCT00189267	Actinic Keratosis	Phase 2	Completed	-	-
NCT00948428	Actinic Keratoses	Phase 3	Completed	-	United States, Arkansas ... More >> Burke Pharmaceutical Research Hot Springs, Arkansas, United States, 71913 United States, California Associates in Research, Inc. Fresno, California, United States, 93720 Skin Surgery Medical Group, Inc. San Diego, California, United States, 92117 United States, Colorado Cherry Creek Research, Inc. Denver, Colorado, United States, 80209 United States, Florida FXM Research Corp. Miami, Florida, United States, 33175 United States, Georgia MedaPhase, Inc. Newnan, Georgia, United States, 30263 United States, Indiana Deaconess Clinic, Inc. Evansville, Indiana, United States, 47713 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, New York Mt. Sinai School of Medicine New York, New York, United States, 10029 Derm Research Center of New York, Inc. Stony Brook, New York, United States, 11790 United States, Ohio University Dermatology Consultants, Inc. Cincinnati, Ohio, United States, 45219 United States, Oregon Oregon Medical Research Center, P.C. Portland, Oregon, United States, 97223 United States, Rhode Island Rhode Island Hospital, Dermatopharmacology Division Providence, Rhode Island, United States, 02903 United States, Tennessee Dermatology Associates of Knoxville, P.C. Knoxville, Tennessee, United States, 37917 Tennessee Clinical Research Center Nashville, Tennessee, United States, 37215 United States, Texas DermResearch, Inc. Austin, Texas, United States, 78759 Suzanne Bruce & Associates, P.A. Houston, Texas, United States, 77056 Dermatology Clinical Research Center of San Antonio San Antonio, Texas, United States, 78229 United States, Utah Dermatology Research Center, Inc. Salt Lake City, Utah, United States, 84124 United States, Washington Premier Clinical Research Spokane, Washington, United States, 99204 Less <<
NCT01151956	-		Completed	-	-
NCT00707174	Cancer Lentig... More >>o Maligna Less <<	Not Applicable	Completed	-	United States, Utah ... More >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT01792505	Malignant Glioma	Phase 1	Completed	-	United States, California ... More >> Cedars Sinai Medical Center Los Angeles, California, United States, 90048 Less <<
NCT01212562	-		Completed	-	Greece ... More >> Department for Skin and Venereal Diseases, University Hospital Ioannina, Greece, 45110 Less <<
NCT01720407	Lentigo Maligna Melanoma (Head... More >> or Neck) Less <<	Phase 3	Recruiting	August 2022	France ... More >> CHU Recruiting Besançon, France Principal Investigator: François AUBIN CHU Hôpital Haut-Lévêque Terminated Bordeaux, France CHU Hôpital Saint André Recruiting Bordeaux, France Principal Investigator: Marie BEYLOT-BARRY AP-HP Hôpital Ambroise Paré Recruiting Boulogne Billancourt, France Principal Investigator: Philippe SAIAG CHU Recruiting Brest, France Principal Investigator: Laurent MISERY CHRU Withdrawn Caen, France CHU Michallon Recruiting Grenoble, France Principal Investigator: Marie-Thérèse LECCIA CH Recruiting Le Mans, France Principal Investigator: Hervé MAILLARD CHRU Recruiting Lille, France Principal Investigator: Laurent MORTIER CHU Recruiting Limoges, France Principal Investigator: Christophe BEDANE CHU Recruiting Lyon sud, France Principal Investigator: Luc THOMAS AP-HM Recruiting Marseille, France Principal Investigator: Jean-Jacques GROB CHU Recruiting Montpellier, France Principal Investigator: Bernard GUILLOT Centre Hospitalier Universitaire de Nantes Recruiting Nantes, France, 44000 Principal Investigator: Brigitte Dréno, MD, PhD CHU Recruiting Nice, France Principal Investigator: Jean-Philippe LACOUR CHU Recruiting Orléans, France Principal Investigator: Guido BENS AP-HP Hôpital Saint Louis Recruiting Paris, France Principal Investigator: Celeste LEBBE CHU Milétrie Recruiting Poitiers, France Principal Investigator: Ewa WIERZBICKA-HAINAUT CHU Recruiting Reims, France Principal Investigator: Florent GRANGE CHU Pontchaillou Recruiting Rennes, France Principal Investigator: Alain DUPUY CHU Recruiting Saint-Etienne, France Principal Investigator: Frédéric CAMBAZARD Chu (Iucto) Recruiting Toulouse, France Principal Investigator: Nicolas MEYER CHU Recruiting Tours, France Principal Investigator: Laurent MACHET Less <<
NCT02059499	Anal Intraepithelial Neoplasia... More >> High-grade Squamous Intraepithelial Lesion HIV Infection Less <<	Phase 3	Active, not recruiting	March 2020	United States, California ... More >> UCLA CARE Center Los Angeles, California, United States, 90035 UCSF-Mount Zion San Francisco, California, United States, 94115 University of California, San Francisco San Francisco, California, United States, 94143 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Louisiana Louisiana State University Health Sciences Center - New Orleans New Orleans, Louisiana, United States, 70112 United States, Massachusetts Boston Medical Center Boston, Massachusetts, United States, 02118 United States, New York Cornell Clinical Trials Unit, New York Presbyterian Hospital New York, New York, United States, 10065 Weill Medical College of Cornell University New York, New York, United States, 10065 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Washington Benaroya Research Institute at Virginia Mason Medical Center Seattle, Washington, United States, 98101 Puerto Rico University of Puerto Rico San Juan, Puerto Rico, 00936-3027 Less <<
NCT01686152	Actinic Keratosis	Phase 3	Completed	-	United States, Arizona ... More >> Radiant Research, Inc. Tucson, Arizona, United States, 85710 United States, California Encino Research Center Encino, California, United States, 91436 Dermatology Research Associates Los Angeles, California, United States, 90045 Northern California Research Sacramento, California, United States, 95821 Skin Surgery Medical Group, Inc. San Diego, California, United States, 92117 United States, Colorado Longmont Clinic, PC Longmont, Colorado, United States, 80501 United States, Florida Visions Clinical Research Boynton Beach, Florida, United States, 33472 Tampa Bay Medical Research Clearwater, Florida, United States, 33761 Jacksonville Center for Clinical Research Jacksonville, Florida, United States, 32216 International Dermatology Research, Inc. Miami, Florida, United States, 33144 Tory Sullivan, M.D., P.A. N. Miami Beach, Florida, United States, 33162 Park Avenue Dermatology, PA Orange Park, Florida, United States, 32073 Leavitt Medical Associates of Florida dba Ameriderm Research Ormond Beach, Florida, United States, 32174 Radiant Research, Inc. Pinellas Park, Florida, United States, 33781 United States, Georgia MedaPhase, Inc. Newnan, Georgia, United States, 30263 United States, Illinois Altman Dermatology Associates Arlington Heights, Illinois, United States, 60005 United States, Indiana The Indiana Clinical Trials Center Plainfield, Indiana, United States, 46168 United States, Kentucky Dermatology Specialists Research LLC Louisville, Kentucky, United States, 40202 United States, Ohio Radiant Research, Inc. Cincinnati, Ohio, United States, 45249 United States, Oregon Oregon Medical Research Center, PC Portland, Oregon, United States, 97223 United States, Pennsylvania Philadelphia Institute of Dermatology Fort Washington, Pennsylvania, United States, 19034 United States, Rhode Island Omega Medical Research Warwick, Rhode Island, United States, 02886 United States, Texas Research Across America Dallas, Texas, United States, 75234 Less <<
NCT00129519	Basal Cell Carcinoma	Phase 3	Completed	-	United States, California ... More >> Grass Valley, California, United States, 95945 Loma Linda, California, United States, 92354 United States, New York New York, New York, United States, 10016 Less <<
NCT00735462	Genital Warts	Phase 3	Completed	-	-
NCT00674739	-		Completed	-	-
NCT00735462	-		Completed	-	-
NCT00335179	Actinic Keratosis	Phase 2	Completed	-	United States, California ... More >> Loma Linda University Medical Center Loma Linda, California, United States, 92350 Less <<
NCT00828568	Actinic Keratosis	Phase 1	Completed	-	United States, Arizona ... More >> Investigator Site Gilbert, Arizona, United States Investigator Site Tempe, Arizona, United States Investigator Site Tuscon, Arizona, United States United States, Colorado Investigator Site Denver, Colorado, United States United States, Florida Investigator Site Jacksonville, Florida, United States Investigator Site Miami, Florida, United States United States, Indiana Investigator Site Evansvill, Indiana, United States Investigator Site Plainfield, Indiana, United States United States, Kansas Investigator Site Olathe, Kansas, United States Investigator Site Wichita, Kansas, United States United States, Nebraska Investigator Site Omaha, Nebraska, United States United States, Nevada Investigator Site Henderson, Nevada, United States United States, North Carolina Investigator Site Cary, North Carolina, United States Investigator Site Hickory, North Carolina, United States Investigator Site High Point, North Carolina, United States Investigator Site Winston-Salem, North Carolina, United States United States, South Carolina Investigator Site Simpsonville, South Carolina, United States United States, Tennessee Investigator Site Murfreesboro, Tennessee, United States United States, Texas Investigator Site College Station, Texas, United States Investigator Site Tyler, Texas, United States Less <<
NCT00828568	-		Completed	-	-
NCT01788007	Actinic Keratosis	Phase 1	Completed	-	-
NCT00761371	Warts	Phase 4	Completed	-	Belgium ... More >> Départment de Gynécologie-Obstétrique CHU Saint-Pierre Brussels, Belgium, B-1000 Service de Dermatologie CHU Saint-Pierre Brussels, Belgium, B-1000 Service Dermatologie C.H. François Rabelais (César de Paepe) Brussels, Belgium, B-1000 Service de Dermatologie Hôpital Erasme Brussels, Belgium, B-1070 France Service de Dermatologie et Vénéréologie Hôpital Saint Jacques Besancon Cedex, France, F-25030 Cabinet Médical Bordeaux, France, F-33800 Service de Dermatologie, Hôpital Ambroise Paré Boulogne Billancourt, France, F-92100 Service de Maladies Infectieuses Hôpital de la Conception Marseille, France, F-13005 Service de Dermatologie Hôtel Dieu Nantes, France, F-44000 Service de Dermatologie Hôpital de l'Archet II Nice, France, F-06202 Service Dermatologie Hopital COCHIN - Pavillon Tarnier Paris, France, F-75006 Cabinet Médical Paris, France, F-75011 Institut Alfred Fournier Paris, France, F-75014 Cabinet Médical Paris, France, F-75015 Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard Paris, France, F-75018 Service de Dermatologie Hopital Tenon Paris, France, F-75020 Service de Dermatologie Groupe Hospitalier La Grave Toulouse, France, F-31052 Service de Dermatologie Centre Hospitalier de Valence Valence, France, F-26000 Less <<
NCT00384124	Bowens Disease	PHASE2\|PHASE3	UNKNOWN	-	Brooke Army Medical Center Dep... More >>artment of Dermatology, Fort Sam Houston, Texas, 78234, United States Less <<
NCT03206138	Cervical Intraepithelial Neopl... More >>asia 3 Less <<	Not Applicable	Recruiting	October 2018	Korea, Republic of ... More >> Seoul St. Mary's hospital Recruiting Seoul, Korea, Republic of, 06591 Contact: Genexine 031-628-3271 ext 82 yyhwang@genexine.com Principal Investigator: Jong-Sup Park, M.D Principal Investigator: Tae-Jin Kim, M.D Principal Investigator: Jae-Kwan Lee, M.D Principal Investigator: Young Tae Kim, M.D Principal Investigator: Chi-Heum Cho, M.D Less <<
NCT00116649	Keratosis	Phase 4	Completed	-	-
NCT01161888	Lentigo Maligna	PHASE4	COMPLETED	2025-03-12	Dr J Marsden, Queen Elizabeth ... More >>Hospital, Birmingham, B15 2TH, United Kingdom Less <<
NCT03233412	Uterine Cervical Neoplasm	Phase 2	Recruiting	August 7, 2019	Brazil ... More >> Barretos Cancer Hospital Recruiting Barretos, Brazil Contact: Ricardo Reis, PhD Less <<
NCT00601016	Hemangioma, Capillary	Phase 2	Completed	-	Canada, Quebec ... More >> Sainte-Justine Hospital University Center (CHU) Montreal, Quebec, Canada, H3T 1C5 Less <<
NCT01088737	Lentigo Maligna	PHASE2\|PHASE3	UNKNOWN	2025-12-21	Medical University of Graz, De... More >>pt. Dermatology, Graz, 8036, Austria\|Medical University of Graz, Graz, 8036, Austria Less <<
NCT00116649	-		Completed	-	-
NCT03307902	Hepatitis B	Phase 2 Phase 3	Recruiting	December 30, 2018	Hong Kong ... More >> University of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Ivan Hung, MD FRCP 2255 4049 ivanhung@hku.hk Less <<
NCT00941811	HPV	PHASE2	COMPLETED	2025-05-10	Stephan Polterauer, Vienna, A-... More >>1090, Austria Less <<
NCT02301494	Mycosis Fungoides	Not Applicable	Not yet recruiting	August 2019	-
NCT03276832	Metastatic Melanoma ... More >> Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less <<	Early Phase 1	Recruiting	February 15, 2021	United States, Florida ... More >> Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Richard W. Joseph Less <<
NCT02242929	Nodular Basal Cell Carcinoma	Phase 3	Active, not recruiting	December 2022	Netherlands ... More >> Maastricht University medical Centre Maastricht, Limburg, Netherlands, 6202AZ Less <<
NCT00189306	-		Completed	-	-
NCT00774787	Actinic Keratoses	Phase 4	Completed	-	United States, Florida ... More >> Spencer Dermatology and Skin Surgery Saint Petersburg, Florida, United States, 33716 United States, Nevada James Del Rosso Henderson, Nevada, United States, 89129 United States, New York Rigel Dermatology New York, New York, United States, 10016 Less <<
NCT00849992	Actinic Cheilitis	Phase 4	Completed	-	Norway ... More >> St. Olavs Hospital Trondheim, Norway, 7006 Less <<
NCT00865644	Neurofibromatosis Type 1 ... More >> Cutaneous Neurofibromas Less <<	Phase 1	Completed	-	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT00189306	Superficial Basal Cell Carcino... More >>ma Less <<	Phase 3	Completed	-	Australia, New South Wales ... More >> Medical Centre, Concord Hospital Concord, New South Wales, Australia Prince of Wales Hospital Randwick, New South Wales, Australia Australia, Queensland Skin Centre Benowa, Queensland, Australia South East Dermatology Centre Carina Heights, Queensland, Australia 105 Fulham Road Gulliver, Queensland, Australia Princess Alexandra Hospital Woolloongabba, Queensland, Australia Australia, South Australia Flinders Medical Center Bedford Park, South Australia, Australia Queen Elizabeth Hospital Woodville, South Australia, Australia Australia, Victoria Western Hospital Footscray, Victoria, Australia Austin & Repartriation Hospital Heidelburg, Victoria, Australia Australia, Western Australia Freemantle Dermatology Fremantle, Western Australia, Australia 158 South Terrace Perth, Western Australia, Australia Subiaco Clinic Subiaco, Western Australia, Australia New Zealand 103A Mountain Road Epsom, Auckland, New Zealand Birthcare Building Parnell, Auckland, New Zealand Colombo Mansions Christchurch, New Zealand Dermatology Practice Christchurch, New Zealand Skin Institute Limited Takapuna, New Zealand Less <<
NCT02120898	Actinic Keratosis	Phase 3	Completed	-	-
NCT00674739	Genital Warts	Phase 3	Completed	-	-
NCT01861535	Vulvar Intraepithelial Neoplas... More >>ia Less <<	Phase 3	Recruiting	December 2019	Austria ... More >> Dep. of Gynecology and Obstetrics, Landes Frauen- und Kinderklinik Linz Recruiting Linz, Oberösterreich, Austria, 4020 Contact: Peter Oppelt, MD peter.oppelt@gespag.at Sub-Investigator: Angelika Soldan-Salzmann, MD Dep. of Gynecology, Krankenhaus Barmherzige Brüder Graz Recruiting Graz, Styria, Austria, 8020 Contact: Christian Schauer, MD Christian.Schauer@bbgraz.at Principal Investigator: Christian Schauer, MD Department of Obstetrics and Gynecology/ Medical University of Graz Recruiting Graz, Austria, 8036 Contact: Gerda Trutnovsky, MD +43 316 385 ext 81081 gerda.trutnovsky@medunigraz.at Contact: Olaf Reich, MD +43 316 385 ext 81616 olaf.reich@medunigraz.at Principal Investigator: Gerda Trutnovsky, MD Department of Gynecology and Obstetrics, Medical University of Innsbruck Recruiting Innsbruck, Austria, 6020 Contact: Andreas Widschendter, MD +43 50 504 ext 23055 andreas.widschwendter@i-med.ac.at Principal Investigator: Andreas Widschwendter, MD Sub-Investigator: Alexandra Ciresa-König, MD Dep. of Gynecology and Obstetrics, Klinikum Klagenfurt Recruiting Klagenfurt, Austria Contact: Manfred Mörtl Dep. of Gynecology and Obstetrics Recruiting Leoben, Austria Contact: Roland Naglis, MD Contact: George Ralph Dep. of Gynecology, Krankenhaus Barmherzige Schwestern Linz Recruiting Linz, Austria, 4010 Contact: Judith Lafleur, MD judith.lafleur@bhs.at Principal Investigator: Judith Lafleur, MD Dep. of Gynecology and Obstetrics, Landeskrankenhaus Salzburg Recruiting Salzburg, Austria, 5020 Contact: Gerhard Bogner, MD g.bogner@salk.at Principal Investigator: Gerhard Bogner, MD Department of General Gynecology and Gynecology Oncology, Medical University of Vienna Recruiting Vienna, Austria, 1090 Contact: Elmar Joura, MD +43 1 40400 ext 2915 elmar.joura@meduniwien.ac.at Contact: Stephan Polterauer, MD +43 316 40400 stephan.polterauer@meduniwien.ac.at Principal Investigator: Elmar Joura, MD Sub-Investigator: Stephan Polterauer, MD Less <<
NCT00638651	-		Completed	-	-
NCT00774787	-		Completed	-	-
NCT00585247	Port Wine Stain	Not Applicable	Completed	-	United States, California ... More >> Beckman Laser Institute Medical and Surgical Cilnic Irvine, California, United States, 92612 Less <<
NCT00638651	Healthy	Phase 1	Completed	-	United States, Florida ... More >> Mohs, Dermatologic and Laser Surgery Miami, Florida, United States, 33136 Less <<
NCT01203878	Actinic Keratosis	Phase 4	Terminated(Unable to reach tar... More >>get enrollment of 60 subjects) Less <<	-	United States, Colorado ... More >> AboutSkin Dermatology and DermSurgery, PC Englewood, Colorado, United States, 80113 United States, North Carolina Dermatology, Laser & Vein Specialists of the Carolinas Charlotte, North Carolina, United States, 28207 United States, Tennessee Tennessee Clinical Research Center Nashville, Tennessee, United States, 37215 Less <<
NCT00899574	Breast Cancer\|Breast Neoplasms	PHASE2	COMPLETED	2025-06-13	NYU Cancer Institute, New York... More >>, New York, 10016, United States Less <<
NCT01538901	Actinic Keratoses	Phase 4	Terminated(prolonged recruitme... More >>nt phase) Less <<	-	Austria ... More >> Medical University of Vienna, University Clinic of Dermatology Vienna, Austria, 1090 Medical University of Vienna Vienna, Austria, 1090 Less <<
NCT00803907	Carcinoma, Basal Cell	Phase 4	Unknown	February 2013	Brazil ... More >> University of Sao Paulo Recruiting Sao Paulo, Brazil Contact: E M Macedo 11-3069-7871 erickmarcet@yahoo.com.br Principal Investigator: E M Macedo Less <<
NCT00585247	-		Completed	-	-
NCT01203878	-		Terminated(Unable to reach tar... More >>get enrollment of 60 subjects) Less <<	-	-
NCT02689726	HPV 16- and/or HPV 18-Infected... More >> Women With Normal Cytology, ASCUS, or LSIL Less <<	Phase 1	Terminated(Lack of efficacy in... More >> European Phase 2 study) Less <<	-	United States, Kentucky ... More >> University of Louisville Louisville, Kentucky, United States, 40208 United States, North Carolina Wake Research Associates, LLC Raleigh, North Carolina, United States, 27612 United States, Ohio Clinical Research Advantage, Inc./ Columbus Obstetricians and Gynecology, Inc. Columbus, Ohio, United States, 43213 United States, Pennsylvania Planned Parenthood Southeastern Pennsylvania Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT02669459	Cervical Intraepithelial Neopl... More >>asia Less <<	Phase 3	Recruiting	March 2020	Netherlands ... More >> Erasmus Medical center Recruiting Rotterdam, Zuid-Holland, Netherlands, 3015 CE Contact: Meike van de Sande, MD 0031-6-22196507 a.vandesande@erasmusmc.nl Contact: Heleen van Beekhuizen, MD 0031-6-81824400 h.vanbeekhuizen@erasmusmc.nl Less <<
NCT01935310	Photoaging		COMPLETED	2025-08-13	Centro de servicios CES Sabane... More >>ta, Medellín, Antioquia, 050021, Colombia Less <<
NCT01229319	Actinic Keratosis	Phase 4	Unknown	August 2011	United States, New York ... More >> Mount Sinai School of Medicine, Department of Dermatology, Clinical Trials Recruiting New York, New York, United States, 10029 Contact: Amylynne J Frankel, MD 212-241-3288 amylynne.frankel@mssm.edu Contact: Giselle K Singer, BS 212-241-3288 giselle.singer@mssm.edu Principal Investigator: Gary S Goldenberg, MD Less <<
NCT00899574	Breast Cancer\|Breast Neoplasms	PHASE2	COMPLETED	2025-06-13	NYU Cancer Institute, New York... More >>, New York, 10016, United States Less <<
NCT03370406	Carcinoma, Squamous Cell	Phase 1	Recruiting	October 14, 2019	United States, Pennsylvania ... More >> St. Margaret Hospital Dermatology Recruiting Pittsburgh, Pennsylvania, United States, 15238 Contact: Melissa Pugliano-Mauro, MD 412-784-7350 puglianomauroma@upmc.edu Contact: Jeff Plowey, MS, MBA 412-784-7350 ploweyjm2@upmc.edu Principal Investigator: Melissa Pugliano-Mauro, MD Sub-Investigator: Kristin Bibee, MD, PhD Sub-Investigator: Erin Skaros, PA-C Sub-Investigator: Changhyun Kim, MD Sub-Investigator: Jeff Plowey, MS, MBA Less <<
NCT01926496	Actinic Keratosis (AK)	Phase 4	Active, not recruiting	October 2019	-
NCT00941252	Cervical Intraepithelial Neopl... More >>asia Less <<	Phase 2 Phase 3	Completed	-	Austria ... More >> Medical University of Vienna, Dpt. of General Gynecology and Gynecologic Oncology Vienna, Austria, 1090 Less <<
NCT02394132	Lentigo Maligna	Phase 3	Recruiting	August 31, 2021	Australia, New South Wales ... More >> Calvary Mater Newcastle Recruiting Newcastle, New South Wales, Australia, 2298 Contact: Chris Wratten Principal Investigator: Chris Wratten Melanoma Institute Australia Recruiting North Sydney, New South Wales, Australia, 2060 Contact: Pascale Guitera Principal Investigator: Pascale Guitera Skin and Cancer Foundation Recruiting Sydney, New South Wales, Australia, 2010 Contact: Pablo Fernandez-Penas Principal Investigator: Pablo Fernandez Penas Westmead Hospital Recruiting Sydney, New South Wales, Australia, 2145 Contact: Pablo Fernandez-Penas Principal Investigator: Pablo Fernandez Penas St Vincent's Hospital, Sydney Recruiting Sydney, New South Wales, Australia Contact: Gerald Fogarty Principal Investigator: Gerald Fogarty Australia, Queensland Princess Alexandra Hospital Recruiting Brisbane, Queensland, Australia, 4102 Contact: Peter Soyer Principal Investigator: Peter Soyer Australia, South Australia Royal Adelaide Hospital Recruiting Adelaide, South Australia, Australia, 5000 Contact: Shireen Sidhu Principal Investigator: Shireen Sidhu Australia, Victoria The Alfred Hospital Recruiting Melbourne, Victoria, Australia, 3004 Contact: Victoria Mar Principal Investigator: Victoria Mar Brazil Hospital das Clinicas, University of Sao Paulo Recruiting São Paulo, Brazil Contact: Lilian Rocha Principal Investigator: Lilian Rocha New Zealand North Shore Hospital Recruiting Takapuna, Auckland, New Zealand, 0740 Contact: Richard Martin Principal Investigator: Richard Martin Less <<
NCT02385188	Paget Disease, Extramammary	Phase 3	Active, not recruiting	January 2020	Netherlands ... More >> Netherlands Cancer Institute Amsterdam, Netherlands, 1066CX Catharina Ziekenhuis Eindhoven Eindhoven, Netherlands, 5623 EJ University Medical Center Groningen Groningen, Netherlands, 9700RB Leiden University Medical Center Leiden, Netherlands, 2333ZA Radboudumc Nijmegen, Netherlands, 6525HB Erasmus Medical Center Rotterdam, Netherlands, 3000CA University Medical Centre Utrecht Utrecht, Netherlands, 3584 CX Less <<
NCT01283763	Cervical Intraepithelial Neopl... More >>asia Less <<	Phase 3	Terminated(poor recruitment)	January 2018	Austria ... More >> Medical University of Vienna Vienna, Austria, 1090 Less <<
NCT01264731	Melanoma	Phase 1	Completed	-	United States, Virginia ... More >> University of Virginia Charlottesville, Virginia, United States, 22908 Less <<
NCT03289260	Anogenital Human Papillomaviru... More >>s Infection Condyloma Anal Less <<	Phase 3	Not yet recruiting	May 31, 2020	Austria ... More >> Visceral-, Transplant- and Thoracic Surgery Active, not recruiting Innsbruck, Tyrol, Austria, 6020 Less <<
NCT02329171	Cervical Intraepithelial Neopl... More >>asia Less <<	Phase 3	Terminated(Insufficient number... More >> of participants.) Less <<	-	Netherlands ... More >> Maastricht University Medical Centre Maastricht, Netherlands, 6202AZ Less <<
NCT02130323	Cervical Intraepithelial Neopl... More >>asia Less <<	Phase 2 Phase 3	Completed	-	United States, California ... More >> Naval Medical Center San Diego San Diego, California, United States, 92134-5000 Less <<
NCT03760250	Keloid	Phase 2	Not yet recruiting	January 1, 2020	United States, Pennsylvania ... More >> University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Jenny Wei Less <<
NCT02917746	Cervical Intraepithelial Neopl... More >>asia Less <<	Not Applicable	Active, not recruiting	December 2020	Netherlands ... More >> Meander Medical Center Amersfoort, Netherlands Maastricht University Medical Center Maastricht, Netherlands, 6202AZ Erasmus Medical Center Rotterdam, Netherlands Less <<
NCT00189254	Actinic Keratoses		COMPLETED	2025-11-05	-
NCT04809662	Actinic Keratoses		TERMINATED	2023-11-07	University of California Davis... More >>, Sacramento, California, 95816, United States Less <<

CAS No. :	99011-02-6
Formula :	C₁₄H₁₆N₄
M.W :	240.30
SMILES Code :	CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Synonyms :	R 837; S-26308; Vyloma
MDL No. :	MFCD00866946
InChI Key :	DOUYETYNHWVLEO-UHFFFAOYSA-N
Pubchem ID :	57469

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H300-H315-H319
Precautionary Statements:	P501-P270-P264-P280-P337+P313-P301+P310+P330
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

mouse primary keratinocytes	100 ng/ml		To investigate the effect of IL-17A signaling in FXYD3-deficient cells, results showed that IL-17A-induced phosphorylation of p65, p38, and ERK1/2 was reduced in FXYD3-knockout keratinocytes.	PMC9971024
mouse peritoneal macrophages	100 ng/mL	48 hours	To investigate the effect of IL-23 on the expression of IL-17A, IL-17F, IL-22, and IFN-γ in macrophages, results showed that IL-23 significantly promoted the expression of these cytokines.	PMC6251802
GEN2.2 cells	3 µg/ml	24 hours	Evaluate the effect of Imiquimod on TLR7 stimulation, results showed a significant reduction in IFN-α secretion	PMC8784643
BM-pDC cells	5 mg/ml	48 hours	Evaluate the effect of Imiquimod on TLR7 stimulation, results showed a significant reduction in IFN-I secretion	PMC8784643
GEN2.2 cells	1 µM	6 hours	To evaluate the effect of SIDT1 silencing on gene expression, results showed significant downregulation of IFN-I-related genes.	PMC8784643

mice	IMQ-induced psoriasis model	topical application	60 mg/kg	Once a week for three weeks	To investigate the role of FXYD3 in the psoriasis model, results showed that FXYD3-deficient mice exhibited attenuated psoriasis-like phenotypes and reduced inflammation.	PMC9971024
mice	imiquimod-induced psoriasis model	topical application	30 mg/kg	Weekly for 3 weeks	To study the role of IL-23-induced macrophages in the psoriasis model, results showed that IL-23-induced macrophages significantly exacerbated the severity of skin inflammation.	PMC6251802
Mice	Vsir-/- murine psoriasis model	Topical administration	25 mg/kg	Twice a week for one week	Induce psoriasis-like dermatitis and observe the inflammatory response in Vsir-/- mice	PMC7482809
Mice	Imiquimod-induced psoriasis model	Topical application	15 mg/kg	Every other day for 2 weeks	Evaluate the role of SIDT1 in the imiquimod-induced psoriasis model, results showed a significant decrease in disease severity in SIDT1-deficient mice	PMC8784643
Mice	Izumo1R-deficient Treg cell mouse model	Topical application	70 mg/kg	daily for 28 days	To study the Imiquimod-induced skin inflammation model, results showed that Iz1rTrKO mice developed significantly more severe disease, with faster and more pronounced ear swelling and exacerbated skin inflammation.	PMC10083566
mice	imiquimod-induced psoriasis model	topical administration	600 mg/kg/day, 300 mg/kg/day, 150 mg/kg/day	once daily for 5 days	To investigate the pathological role of IL-23-induced macrophages in a psoriasis model, results showed that IL-23-induced macrophages significantly promoted the severity of skin inflammation.	PMC6251802
Mice	Vsir-/- murine psoriasis model	Topical application	30 mg/kg	Once daily for 8 weeks	To induce psoriasis-like dermatitis and evaluate skin inflammatory response	PMC7482809
Mice	Imiquimod-induced psoriasis-like dermatitis model	Topical application	30 mg/kg	Twice daily for 4 days	To assess the impact of SIDT1 deficiency on the imiquimod-induced psoriasis-like dermatitis model, results showed that SIDT1 deficiency significantly reduced disease severity and IFN-I levels.	PMC8784643
Mice	Izumo1R-deficient Treg cell mouse model	Topical application	62.5 mg 5% Imiquimod cream	Every second day for 6 consecutive days	To investigate the role of Izumo1R in Treg cells, particularly its regulatory function in skin inflammation. The results showed that Izumo1R-deficient mice exhibited more severe inflammation in the Imiquimod-induced skin inflammation model.	PMC10083566

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Imiquimod

CAS No.: 99011-02-6

Alternative Products

Product Details of Imiquimod

Safety of Imiquimod

Related Pathways of Imiquimod

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed